Immunomodulatory role of metalloproteinase ADAM17 in tumor development

Area of Science:

• Biochemistry
• Molecular Biology
• Immunology

Background:

• ADAM17 (a disintegrin and metalloproteinase 17) is a transmembrane protease regulating cell surface protein shedding and signaling pathways.
• It influences over 90 substrates, including those critical for tumor formation, development, and immune regulation.
• While recognized as a cancer therapeutic target, ADAM17's immunomodulatory functions in cancer remain incompletely understood.

Purpose of the Study:

• To review the current understanding of ADAM17 structure and its diverse regulatory functions.
• To emphasize the significant, yet often unclear, immunomodulatory roles of ADAM17 in the context of tumor development.
• To discuss emerging therapeutic strategies, including small molecule inhibitors and monoclonal antibodies, targeting ADAM17 for cancer treatment.

Main Methods:

• Literature review and synthesis of recent research on ADAM17.
• Analysis of ADAM17's role in substrate shedding and signal transduction.
• Examination of ADAM17's involvement in tumor biology and immune modulation.

Main Results:

• ADAM17 plays a multifaceted role in cancer, influencing both tumor progression and the tumor immune microenvironment.
• Its substrates are implicated in key oncogenic pathways and immune cell function.
• Targeting ADAM17 presents a promising therapeutic avenue, with ongoing development of specific inhibitors and antibodies.

Conclusions:

• ADAM17 is a critical regulator with significant implications for cancer development and immunity.
• Further elucidation of its immunomodulatory mechanisms is essential for optimizing therapeutic strategies.
• Targeted inhibition of ADAM17 holds potential for novel cancer therapies.